USA flag logo/image

An Official Website of the United States Government

Controlling Inflammation Due to Cardiac Devices

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96314
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
HL099015
Solicitation Year:
N/A
Solicitation Topic Code:
NHLBI
Solicitation Number:
N/A
Small Business Information
NOVELMED THERAPEUTICS, INC.
11000 Cedar Avenue, 135 CLEVELAND, OH 44106-0000
View profile »
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2010
Title: Controlling Inflammation Due to Cardiac Devices
Agency: HHS
Contract: 1R44HL099015-01
Award Amount: $420,195.00
 

Abstract:

DESCRIPTION (provided by applicant): NovelMed's lead drug candidate prevents biomaterials induced cellular activation. Activated cells release inflammatory mediators that are responsible for pathological trauma that leads to cardiac, lung, liver, and brain injuries during surgical procedures that require cardiac devices. Our findings provide convincing support for developing YalcixiMab as a treatment to prevent biomaterial-induced inflammation that occurs during surgical procedures. CPB circuits are used du ring various procedures for heart transplant, and valve replacements. Treatment of blood with YalcioMab prior to the extracorporeal circulation prevents complement activation, neutrophil activation, monocyte activation, platelet activation and the formatio n of leukocyte-platelet aggregates. The drug also prevents the release of potent inflammatory mediators such as TNF-1. . PUBLIC HEALTH RELEVANCE: NovelMed is developing treatments that will reduce/prevent complications that arise when blood is expos ed to biomaterial surfaces of the cardiac devices. Cardiopulmonary bypass circuits are utilized in several cardiac surgeries as a heart-lung machine while surgeons perform procedures on the empty heart. The ultimate objective of this proposal is the develo pment of technologies that will improve the manufacturing of engineered human tissues

Principal Investigator:

Rekha Bansal
4404779874
REKHA@NOVELMED.COM

Business Contact:

Ganesh Iyer
rekha@novelmed.com
Small Business Information at Submission:

NOVELMED THERAPEUTICS, INC.
NOVELMED THERAPEUTICS, INC. 2265 ENTERPRISE PKWY TWINSBURG, OH 44087

EIN/Tax ID: 142159780
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No